| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-12-15 | BI 836858 in combination with decitabine | acute myeloid leukemia (AML) | 2 | Boehringer Ingelheim (Germany) | Cancer - Oncology |
| 2015-12-14 | IMO-2125 in combination with ipilimumab | patients with previously treated metastatic melanoma | 1-2 | Idera Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2015-12-14 | PINTA 745 | protein energy wasting in patients with end stage renal disease | 1-2 | Atara Biotherapeutics (USA - CA) | Kidney diseases - Renal diseases |
| 2015-12-14 | SGX301 (synthetic hypericin) | cutaneous T-cell lymphoma | 3 | Soligenix (USA - NJ) | Cancer - Oncology |
| 2015-12-13 | SGN-LIV1A | LIV-1-expressing metastatic breast cancer | 1 | Seattle Genetics (USA - WA) | Cancer - Oncology |
| 2015-12-11 | BioChaperone Lispro® U200 | diabetes | 1b | Adocia (France) Eli Lilly (USA - IN) | Metabolic diseases |
| 2015-12-11 | human pegivirus 2 (HPgV-2) | hepatitis C | Abbott (USA - IL) University of California San Francisco (UCSF) (USA - CA) | Infectious diseases | |
| 2015-12-11 | predictive biomarker signature for vantictumab (anti-Fzd7, OMP-18R5) | breast cancer | OncoMed Pharmaceuticals (USA - CA) | Cancer - Oncology | |
| 2015-12-10 | CER-001 | familial primary hypoalphalipoproteinemia (FPHA) | 3 | Cerenis Therapeutics (France) | Cardiovascular diseases - Metabolic diseases - Genetic diseases - Rare diseases |
| 2015-12-10 | Zalmoxis® - investigational cell therapy product TK | high risk leukemia | 1-2 | MolMed (Italy) | Cancer - Oncology |
| 2015-12-10 | TW001 - edaravone | amyotrophic lateral sclerosis | Treeway (The Netherlands) | Neurodegenerative diseases - Rare diseases | |
| 2015-12-10 | JNJ-64041757/ADU-214 | non small cell lung cancer | 1 | Janssen Research & Development, a J&J company (USA - NJ) | |
| 2015-12-09 | daratumumab | diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL) | 2 | Janssen Research & Development, a J&J company (USA - NJ) | Cancer - Oncology |
| 2015-12-09 | ADX88178 | preclinical | Addex Therapeutics (Switzerland) | Neurodegenerative diseases - CNS diseases | |
| 2015-12-09 | avelumab (MSB0010718C) | unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro esophageal Junction | 3 | Pfizer (USA - NY) Merck KGaA (Germany) | Cancer - Oncology |
| 2015-12-09 | avelumab (MSB0010718C) | unresectable, recurrent or metastatic adenocarcinoma of the stomach, or of the gastro esophageal junction | 3 | Pfizer (USA - NY) Merck KGaA (Germany) | Cancer - Oncology |
| 2015-12-08 | Alprolix® (eftrenonacog alfa - long-lasting recombinant Factor IX Fc fusion protein (rFIXFc) - BIIB 029 | hemophilia B | Biogen (USA - MA) Swedish Orphan Biovitrum SOBI (Sweden) | Rare diseases - Genetic diseases - Hematological diseases | |
| 2015-12-08 | varlilumab and Tecentriq® (atezolizumab) (MPDL3280A) | unresectable stage III or IV renal cell carcinoma (RCC)unresectable stage III or IV melanoma, triple negative breast cancer, bladder cancer, head and neck cancer or non-small cell lung cancer (NSCLC) | 1- 2 | Celldex Therapeutics (USA - NJ) | Cancer - Oncology |
| 2015-12-08 | nintedanib | systemic sclerosis | 3 | Boehringer Ingelheim (Germany) | Autoimmune diseases - Rare diseases |
| 2015-12-08 | eltoprazine | elderly patients with Alzheimer's dementia who are aggressive | 2 | Amarantus BioScience (USA – CA) | Neurodegenerative diseases |
